Literature DB >> 21821029

Aurora-A phosphorylates hnRNPK and disrupts its interaction with p53.

Kai-Wei Hsueh1, Shu-Ling Fu, Chi-Ying F Huang, Chao-Hsiung Lin.   

Abstract

Amplification of Aurora-A, encoding a cell cycle-regulating kinase, has been reported in human cancers. Although Aurora-A is known to directly phosphorylate and down-regulate p53, the detailed mechanism remains unclear. Here we show that Aurora-A phosphorylates hnRNPK, a transcriptional coactivator of p53, on serine 379. This phosphorylation does not affect the post-transcriptional activity or cellular localization of hnRNPK, but disrupts its interaction with p53. Inverse correlation between Aurora-A activity and hnRNPK-p53 interaction was further demonstrated in DNA-damaged cells. Our results provide an alternative mechanism, whereby via phosphorylating hnRNPK Aurora-A participates in regulating p53 activity during DNA damage.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21821029     DOI: 10.1016/j.febslet.2011.07.031

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

Review 1.  Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors.

Authors:  Kiyoko Umene; Kouji Banno; Iori Kisu; Megumi Yanokura; Yuya Nogami; Kosuke Tsuji; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Wataru Yamagami; Hiroyuki Nomura; Eiichiro Tominaga; Nobuyuki Susumu; Daisuke Aoki
Journal:  Biomed Rep       Date:  2013-03-27

Review 2.  Nuclear localisation of Aurora-A: its regulation and significance for Aurora-A functions in cancer.

Authors:  Francesco Davide Naso; Dalila Boi; Camilla Ascanelli; Georgiana Pamfil; Catherine Lindon; Alessandro Paiardini; Giulia Guarguaglini
Journal:  Oncogene       Date:  2021-05-13       Impact factor: 9.867

3.  ATM targets hnRNPK to control p53.

Authors:  Melanie Blasius; Jiri Bartek
Journal:  Cell Cycle       Date:  2013-04-02       Impact factor: 4.534

4.  Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype.

Authors:  Feimeng Zheng; Caifeng Yue; Guohui Li; Bin He; Wei Cheng; Xi Wang; Min Yan; Zijie Long; Wanshou Qiu; Zhongyu Yuan; Jie Xu; Bing Liu; Qian Shi; Eric W-F Lam; Mien-Chie Hung; Quentin Liu
Journal:  Nat Commun       Date:  2016-01-19       Impact factor: 14.919

Review 5.  Functional Significance of Aurora Kinases-p53 Protein Family Interactions in Cancer.

Authors:  Kaori Sasai; Warapen Treekitkarnmongkol; Kazuharu Kai; Hiroshi Katayama; Subrata Sen
Journal:  Front Oncol       Date:  2016-11-25       Impact factor: 6.244

Review 6.  Aurora kinases: novel therapy targets in cancers.

Authors:  Anqun Tang; Keyu Gao; Laili Chu; Rui Zhang; Jing Yang; Junnian Zheng
Journal:  Oncotarget       Date:  2017-04-04

7.  hnRNPK S379 phosphorylation participates in migration regulation of triple negative MDA-MB-231 cells.

Authors:  Hsin-Yu Tsai; Shu-Ling Fu; Ling-Ming Tseng; Jen-Hwey Chiu; Chao-Hsiung Lin
Journal:  Sci Rep       Date:  2019-05-20       Impact factor: 4.379

8.  Mitotic Kinases and p53 Signaling.

Authors:  Geun-Hyoung Ha; Eun-Kyoung Yim Breuer
Journal:  Biochem Res Int       Date:  2012-07-19

9.  Chalcones Repressed the AURKA and MDR Proteins Involved in Metastasis and Multiple Drug Resistance in Breast Cancer Cell Lines.

Authors:  Tatiana Takahasi Komoto; Tayná Minervina Bernardes; Thaís Balthazar Mesquita; Luis Felipe Buso Bortolotto; Gabriel Silva; Tamires Aparecida Bitencourt; Seung Joon Baek; Mozart Marins; Ana Lúcia Fachin
Journal:  Molecules       Date:  2018-08-13       Impact factor: 4.411

10.  ATM-dependent phosphorylation of heterogeneous nuclear ribonucleoprotein K promotes p53 transcriptional activation in response to DNA damage.

Authors:  Abdeladim Moumen; Christine Magill; Katherine L Dry; Stephen P Jackson
Journal:  Cell Cycle       Date:  2013-01-23       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.